TY - JOUR T1 - Infliximab in refractory psoriatic arthritis with severe psoriasis: a 2-year experience JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - 270 LP - 271 DO - 10.1136/ard.2006.058735 VL - 66 IS - 2 AU - Paraskevi V Voulgari AU - Aliki I Venetsanopoulou AU - Efstratios K Epagelis AU - Yannis Alamanos AU - Ioanna Takalou AU - Alexandros A Drosos Y1 - 2007/02/01 UR - http://ard.bmj.com/content/66/2/270.abstract N2 - Infliximab was shown to be effective and safe in controlled trials of psoriatic arthritis (PsA).1–,4 In an open-label study, we reported a notable clinical benefit accompanied by clearing and healing of psoriatic skin lesions.5 Thus, we conducted this study to evaluate the efficacy and safety of infliximab in patients with active PsA and recalcitrant psoriasis in whom treatment with disease-modifying antirheumatic drugs had failed. Thirty two patients who had a negative purified protein derivative skin test and normal chest radiographs were included. All had an active disease, defined as ⩾6 tender or swollen joints count, psoriasis area and severity index (PASI) score ⩾10,6 and erythrocyte sedimentation rate ⩾28 mm Hg/h or C reactive protein concentration … ER -